Market Chatter: Novo Nordisk Plans Online Launch for New Weight-Loss Pill

MT Newswires Live

2025/10/04

Novo Nordisk (NVO) plans to launch its oral obesity pill, nicknamed "Wegovy-in-a-pill," via telehealth platforms such as Ro and WeightWatchers (WW) once it gains US approval, with sales expected in early 2026, Bloomberg reported Friday, citing an interview with Dave Moore, the company's US operations chief.

The company is considering subscription-style offerings that would deliver six- to 12-month supplies at reduced prices, the report said.

Novo Nordisk didn't immediately respond to a request for comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 59.80, Change: +1.06, Percent Change: +1.80

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2572687971"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572687971\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572687971?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-04 02:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572687971","market":"fut","top_or_hot":-1,"title":"Market Chatter: Novo Nordisk Plans Online Launch for New Weight-Loss Pill","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> (NVO) plans to launch its oral obesity pill, nicknamed \"Wegovy-in-a-pill,\" via telehealth platforms such as Ro and WeightWatchers (WW) once it gains US approval, with sales expected in early 2026, Bloomberg reported Friday, citing an interview with Dave Moore, the company's US operations chief.</p><p>The company is considering subscription-style offerings that would deliver six- to 12-month supplies at reduced prices, the report said.</p><p>Novo Nordisk didn't immediately respond to a request for comment from MT Newswires.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p><p>Price: 59.80, Change: +1.06, Percent Change: +1.80</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Market Chatter: Novo Nordisk Plans Online Launch for New Weight-Loss Pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarket Chatter: Novo Nordisk Plans Online Launch for New Weight-Loss Pill\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-10-04 02:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> (NVO) plans to launch its oral obesity pill, nicknamed \"Wegovy-in-a-pill,\" via telehealth platforms such as Ro and WeightWatchers (WW) once it gains US approval, with sales expected in early 2026, Bloomberg reported Friday, citing an interview with Dave Moore, the company's US operations chief.</p><p>The company is considering subscription-style offerings that would deliver six- to 12-month supplies at reduced prices, the report said.</p><p>Novo Nordisk didn't immediately respond to a request for comment from MT Newswires.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p><p>Price: 59.80, Change: +1.06, Percent Change: +1.80</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKVL7J92.USD","symbol_name":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2572687971","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572687971","pubTimestamp":1759516619,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Novo Nordisk  plans to launch its oral obesity pill, nicknamed \"Wegovy-in-a-pill,\" via telehealth platforms such as Ro and WeightWatchers  once it gains US approval, with sales expected in early 2026, Bloomberg reported Friday, citing an interview with Dave Moore, the company's US operations chief.The company is considering subscription-style offerings that would deliver six- to 12-month supplies at reduced prices, the report said.Novo Nordisk didn't immediately respond to a request for comment from MT Newswires.Price: 59.80, Change: +1.06, Percent Change: +1.80","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","NVO.AU":"NOVO RESOURCES CORP-CDI","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4532":"文艺复兴科技持仓","BK4599":"减肥药","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4192":"特殊消费者服务","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","NVO":"诺和诺德","WW":"WW International, Inc.","BK7104":"黄金","BK4007":"制药","BK4588":"碎股","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4585":"ETF&股票定投概念"},"translate_title":"市场热议：诺和诺德计划在线推出新型减肥药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WW":1,"NVO.AU":1,"NVO":1.5},"content_text":"Novo Nordisk (NVO) plans to launch its oral obesity pill, nicknamed \"Wegovy-in-a-pill,\" via telehealth platforms such as Ro and WeightWatchers (WW) once it gains US approval, with sales expected in early 2026, Bloomberg reported Friday, citing an interview with Dave Moore, the company's US operations chief.The company is considering subscription-style offerings that would deliver six- to 12-month supplies at reduced prices, the report said.Novo Nordisk didn't immediately respond to a request for comment from MT Newswires.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: 59.80, Change: +1.06, Percent Change: +1.80","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}